21results about "General/multifunctional contrast agents" patented technology

A liposomal nanocarrier delivery system for targeting an active CD44 molecule, preparation method therefor, and uses thereof. The surface of the liposome is partially modified by a targeting ligand, wherein the targeting ligand is a ligand that can be specifically combined with the active CD44 molecule. The liposomal nanocarrier delivery system can be used for diagnosing, preventing, and treating vulnerable plaque or diseases related to vulnerable plaque.

Provided are androstane and dihydrotestosterone compounds functionalized with carbocyclic groups or heterocyclic groups that may be saturated or unsaturated. The compounds may be used in methods of inhibiting cell growth of malignant cells and / or hyperplastic cells and / or treating individuals having diseases associated with malignant cell growth (e.g., cancer, such as, for example, prostate cancer) and / or hyperplastic cell growth and / or molecular imaging of malignant cells and / or hyperplastic cells and / or inducing degradation of a target protein. Also provided are compositions.

Relates to anti-transthyretin (TTR) binding proteins and their use. Transthyretin amyloidosis is characterized by the progressive deposition of the plasma protein transthyretin in the myocardium, peripheral nerves and / or other tissues, ultimately leading to death from congestive heart failure and polyneuropathy. The present invention provides binding proteins that can specifically bind to isoaspartic acid residues in the transthyretin protein, as well as their therapeutic, diagnostic and prognostic uses.

The present disclosure relates to molecular probes for nucleic acid detection, and preparation and uses thereof. In particular, described herein is a molecular probe for detection of a nucleic acid, comprising, (1) a molecular probe carrier which comprises a cell penetrating peptide and a detectable label coupled to the cell penetrating peptide, and (2) a targeting oligonucleotide, wherein the targeting oligonucleotide is attached to the molecular probe carrier. Also described herein are a method for preparing the molecular probe, a method for detection of a nucleic acid, and a kit for detection of a nucleic acid.

Disclosed herein is an antibody-conjugate comprising a monoclonal antibody that specifically binds to GD2 and comprises a heavy chain and a light chain comprising heavy and light chain variable regions set forth as SEQ ID NOs: 3 and 4, respectively. The monoclonal antibody can be conjugated to a near-infrared fluorescent dye and diethylenetriaminepentaacetic acid (DTPA). In several aspects, the antibody-conjugate further comprising Indium-111 (111In) chelated by the DTPA. The antibody-conjugate specifically binds to GD2, and is useful, for example, in radio-guided and fluorescent-guided surgical techniques for intraoperative detection of GD2-positive cancer tissue.

Provided herein are compositions, methods, and uses involving antibodies that specifically bind the Galectin-3 (LGALS3) carbohydrate binding domain (CBD). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.

The present disclosure provides multifunctional compounds for use in medical imaging and therapy, which include two or more of (i) a chelating ligand moiety (CL), (ii) an optical probe moiety (OP), and (iii) a biological targeting moiety (BT).The present disclosure further provides related compositions and methods.The present disclosure provides multifunctional compounds useful in medical imaging and therapy, including pre-, in-situ, and post-surgery medical imaging and therapy.

The present invention relates to zwitterionic metal chelators and their use as imaging agents, diagnostic agents, chemical processing agents, and therapeutic agents. These zwitterionic metal chelators have desirable properties of maximizing solubility in aqueous environments, minimizing non-specific interactions, and retaining targeting ability, resulting in improved performance in a variety of medical, agricultural, and chemical processes. In vivo and medical applications, the zwitterionic metal chelators improve signal-to-background ratios and therapeutic windows compared to other metal chelators, while retaining high stability.

Gas vesicles, protein variants and related compositions methods and systems for singleplexed and / or multiplexed ultrasound imaging of a target site in which a gas vesicle provides contrast for the imaging which is modifiable by application of a selectable acoustic collapse pressure value of the gas vesicle.

The present invention provides a composition comprising: —at least one gel-forming hydrophobic carbohydrate ester or an analogue thereof based on mono-, di-, and tri-saccharides, or mixtures thereof; —at least one polymer; and —at least one solvent being mixable with water; wherein the composition is a ECell being a hydrophobic gel-depot having the ability to take up water by means of said at least one solvent being mixable with water and having the ability to self-expand by formation of water pores, channels, and / or cavities.

A fluorescence-magnetic resonance dual-modality contrast agent, a preparation method thereof and the use thereof. The contrast agent has the following structure: X-L-Y, wherein: formula (I); R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12 are each independently selected from H, halogen, OH, NH2, COOH, CONH2, NO2, CN, and low alkyl groups, the low alkyl groups can be substituted with halogen, OH, NH2, COOH, CONH2, SO3H, NO2, and CN, wherein R3 and R4, taken together with the carbon atoms to which they are attached, may form a phenyl group or a heterocyclic group; R7 and R8, taken together with the carbon atoms to which they are attached, may form a phenyl group or heterocyclic group; L is a linking group; and Y is a metal chelate.

This invention discloses a MEC nanoprobe, its preparation method, and its applications. The MEC nanoprobe is composed of Mn... 3+ The sample was prepared using TCPP, Erastin, and CD133mab, with CD133mab coupled to the surface. The preparation method involved adding Mn... 3+ Mn-TCPP-MOF was synthesized by stirring TCPP in an N,N-dimethylformamide solution containing acetic acid; Erastin was then added and stirred at room temperature, followed by centrifugation, washing, and redispersing in deionized water; the amide bonds were then activated via EDC / NHS and coupled to CD133mAb to obtain MEC nanoprobes. The combined application of this MEC nanoprobe with a TGFβ1R inhibitor can block both the classical ferroptosis resistance pathway and CAF-related pathways, achieving dual-channel blockade of ferroptosis resistance in pancreatic cancer. Furthermore, dual-modal imaging enables semi-quantitative in vivo visualization assessment of ferroptosis resistance, demonstrating promising clinical application prospects.

The present invention provides a conjugation molecule comprising at least two single variable antibody domains that target receptors present on fibrogenic effector cells, including activated myofibroblasts and similar and / or related profibrosis cells and / or contractile cells. [Solution] The present invention relates to an internalized binding molecule for cell-specific targeted delivery of anti-fibrotic substances. The present invention also relates to a binding molecule comprising at least two single variable antibody domains, each targeting a receptor on fibrillating effector cells. The present invention further relates to nucleic acids encoding such binding molecules, host cells for the expression of such binding molecules, and methods for preparing such binding molecules. The present invention further relates to pharmaceutical compositions comprising such binding molecules, and the use of such binding molecules and / or pharmaceutical compositions, in particular, for preventive, therapeutic, or diagnostic purposes.

This application relates to the preparation and application of a gambogeylic acid formulation targeting malignant tumors. It employs a three-layer structure: the core is a gambogeylic acid-black phosphorus quantum dot complex, possessing both chemotherapy and photothermal therapy functions; the middle layer consists of cryogenically frozen NK92 MI cell-derived nanovesicles, providing natural immune targeting and killing capabilities; the outer shell is a hyaluronic acid chelate, enabling active targeting and pH / photothermal responsive drug release. The core of its preparation method lies in using coaxial electrospray technology to form the three layers in one step, resulting in a highly efficient process and good formulation stability. This formulation can achieve synergistic photothermal-chemo-immunotherapy and simultaneously possesses near-infrared fluorescence and photoacoustic multimodal imaging capabilities, effectively solving the problems of poor targeting, significant toxic side effects, and lack of real-time monitoring associated with traditional chemotherapy. It demonstrates significant advantages and application potential in the precision treatment and diagnosis of solid tumors.

The present disclosure is directed to pharmaceutical and diagnostic compositions comprising macropinocytosis selective non-binding protein-drug conjugates. These non-binding protein-drug conjugates comprise a non-binding fibronectin type III (FN3) domain coupled to a pharmaceutically active moiety or a diagnostic moiety. The disclosure is also directed to methods of treatment and diagnosis that involve administering the pharmaceutical compositions described herein to a subject in need.